Also trades as: NAMS (NASDAQ) · $vol 25M
NAMSW NASDAQ
NewAmsterdam Pharma Company N.V.
1W: -11.5%
1M: -22.5%
3M: -13.3%
YTD: -28.3%
1Y: +35.7%
3Y: +652.7%
5Y: +1257.4%
$16.56
-2.44 (-12.84%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$3.0B
52W Range10.23-30.45
Volume0
Avg Volume755
Beta0.08
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Harvey Davidson Facp.
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-10
Websitenewamsterdampharma.com
Gooimeer 2-35
Naarden, NH 1411 DC
NL
Naarden, NH 1411 DC
NL
31 35 206 2971
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Latest News
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| LANGE LOUIS G | S-Sale | 44,173 | $30.41 | 2026-03-11 |
| LANGE LOUIS G | S-Sale | 446 | $31.23 | 2026-03-11 |
| LANGE LOUIS G | X-InTheMoney | 44,619 | $11.50 | 2026-03-09 |
| LANGE LOUIS G | X-InTheMoney | 44,619 | $11.50 | 2026-03-09 |
| Kastelein Johannes J | M-Exempt | 101,409 | — | 2026-03-09 |